FibroGen CEO Enrique Conterno's 2021 pay slips 15% to $10M
FibroGen reports 2021 executive compensation
By ExecPay News
Published: April 28, 2022
FibroGen reported fiscal year 2021 executive compensation information on April 28, 2022.
In 2021, seven FibroGen executives received on average a compensation package of $4.5M, a 8% increase compared to previous year.
Average pay of disclosed executives at FibroGen
Enrique Conterno, Chief Executive Officer, received $10M in total, which decreased by 15% compared to 2020. 46% of Conterno's compensation, or $4.7M, was in option awards. Conterno also received $422K in non-equity incentive plan, $825K in salary, $4.3M in stock awards, as well as $58K in other compensation.
For fiscal year 2021, the median employee pay was $174,414 at FibroGen. Therefore, the ratio of Enrique Conterno's pay to the median employee pay was 60 to one.
Christine L. Chung, Senior Vice President, China Operations, received a compensation package of $4.7M, which increased by 64% compared to previous year. 43% of the compensation package, or $2M, was in option awards.
Mark Eisner, Chief Medical Officer, earned $3.8M in 2021, a 4% decrease compared to previous year.
Pat Cotroneo, Chief Financial Officer, received $3.8M in 2021, which increases by 29% compared to 2020.
Elias Kouchakji, Senior Vice President, Clinical Development, Drug Safety, and Pharmacovigilance, earned $3.2M in 2021, a 10% increase compared to previous year.
Thane Wettig, Chief Commercial Officer, received $3.2M in 2021, which decreases by 21% compared to 2020.
Juan Graham, Chief Financial Officer, earned $2.3M in 2021.
Related executives
Enrique Conterno
FibroGen
Chief Executive Officer
Christine Chung
FibroGen
Senior Vice President, China Operations
Pat Cotroneo
FibroGen
Chief Financial Officer
Mark Eisner
FibroGen
Chief Medical Officer
Juan Graham
FibroGen
Chief Financial Officer
Elias Kouchakji
FibroGen
Senior Vice President, Clinical Development, Drug Safety, and Pharmacovigilance
Thane Wettig
FibroGen
Chief Commercial Officer
You may also like
Source: SEC filing on April 28, 2022.